Key result
Hederasaponin B and Hedera helix extract show antiviral activity against EV71 in vero cells.
Why the study?
The antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated to identify novel drug candidates for HFMD.
Does hederasaponin B exhibit antiviral activity against Enterovirus 71 subgenotypes C3 and C4a in vitro?
Does hederasaponin B exhibit antiviral activity against Enterovirus 71 subgenotypes C3 and C4a in vitro?
Hederasaponin B demonstrates in vitro antiviral activity against EV71, suggesting potential as a candidate for treating hand, foot and mouth disease.
May support preclinical EV71 antiviral development; leaves open clinical translation from in vitro data alone.
Enterovirus 71 (EV71) is the predominant cause of hand, foot and mouth disease (HFMD). The antiviral activity of hederasaponin B from Hedera helix against EV71 subgenotypes C3 and C4a was evaluated in vero cells. In the current study, the antiviral activity of hederasaponin B against EV71 C3 and C4a was determined by cytopathic effect (CPE) reduction method and western blot assay. Our results demonstrated that hederasaponin B and 30% ethanol extract of Hedera helix containing hederasaponin B showed significant antiviral activity against EV71 subgenotypes C3 and C4a by reducing the formation of a visible CPE. Hederasaponin B also inhibited the viral VP2 protein expression, suggesting the inhibition of viral capsid protein synthesis.These results suggest that hederasaponin B and Hedera helix extract containing hederasaponin B can be novel drug candidates with broad-spectrum antiviral activity against various subgenotypes of EV71.
No takes yet. Share an insight, caveat, or question.
Song et al. (2014) studied Enterovirus 71 (EV71) infection. Hederasaponin B and 30% ethanol extract of Hedera helix was evaluated on Antiviral activity (cytopathic effect reduction and viral VP2 protein expression). Hederasaponin B and 30% ethanol extract of Hedera helix showed significant antiviral activity against EV71 subgenotypes C3 and C4a in vero cells by reducing visible cytopathic effect.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: